Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Enteric-coated Mycophenolate Sodium in Renal Transplant Patients
NCT00149916Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2000
- Primary completion
- Apr 2004
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of mycophenolate sodium in kidney transplant rejection, sponsored by Novartis. Primary endpoint: Gastro-intestinal tolerability. Started Apr 2000; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00149916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00149916.